Literature DB >> 12077076

Centrally acting agents and visceral sensitivity.

J Fioramonti1, L Bueno.   

Abstract

The evidence relating to the site and mechanism of action of "centrally acting" agents which may affect visceral sensitivity is reviewed. Antidepressant drugs such as amitriptyline as well as the newer selective serotonin reuptake inhibitors are thought to act at the level of the CNS. Opiates, including morphine as well as compounds such as trimebutine or fedotozine designed for therapeutic use in irritable bowel syndrome, are effective in reducing visceral nociception. Cytokines in the CNS are known to be involved in the modulation of pain and there is also evidence to suggest that centrally acting cytokines may play a role in the production of visceral hypersensitivity. Consequently, they may provide an interesting target for future research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077076      PMCID: PMC1867729          DOI: 10.1136/gut.51.suppl_1.i91

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  65 in total

1.  Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat.

Authors:  B Bonaz; P J Rivière; V Sinniger; X Pascaud; J L Junien; J Fournet; C Feuerstein
Journal:  Neurogastroenterol Motil       Date:  2000-04       Impact factor: 3.598

2.  Opioid pharmacology of the antinociceptive effects of loperamide in mice.

Authors:  M. Takasuna; S.S. Negus; B.R. DeCosta; J.H. Woods
Journal:  Behav Pharmacol       Date:  1994-04       Impact factor: 2.293

3.  Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents.

Authors:  M J Field; R J Oles; A S Lewis; S McCleary; J Hughes; L Singh
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

4.  TNF-alpha activates solitary nucleus neurons responsive to gastric distension.

Authors:  G S Emch; G E Hermann; R C Rogers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-09       Impact factor: 4.052

5.  Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.

Authors:  A B Gorelick; S S Koshy; F G Hooper; T C Bennett; W D Chey; W L Hasler
Journal:  Am J Physiol       Date:  1998-09

6.  Effect of fedotozine on the cardiovascular pain reflex induced by distension of the irritated colon in the anesthetized rat.

Authors:  A Langlois; L Diop; P J Rivière; X Pascaud; J L Junien
Journal:  Eur J Pharmacol       Date:  1994-12-27       Impact factor: 4.432

7.  Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat.

Authors:  L Diop; P J Rivière; X Pascaud; J L Junien
Journal:  Eur J Pharmacol       Date:  1994-12-12       Impact factor: 4.432

8.  Loperamide treatment of the irritable bowel syndrome.

Authors:  N Hovdenak
Journal:  Scand J Gastroenterol Suppl       Date:  1987

9.  Interactions of trimebutine with guinea-pig opioid receptors.

Authors:  F Roman; X Pascaud; J E Taylor; J L Junien
Journal:  J Pharm Pharmacol       Date:  1987-05       Impact factor: 3.765

10.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

View more
  7 in total

Review 1.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

2.  Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.

Authors:  Victoria P Y Tan; Tin K Cheung; Wai M Wong; Roberta Pang; Benjamin C Y Wong
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

3.  Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.

Authors:  Jill P Smith; Douglas Field; Sandra I Bingaman; Robert Evans; David T Mauger
Journal:  J Clin Gastroenterol       Date:  2013-04       Impact factor: 3.062

4.  Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.

Authors:  Revital Kariv; Elisa Tiomny; Roman Grenshpon; Roy Dekel; Galit Waisman; Yehuda Ringel; Zamir Halpern
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

5.  Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic Acid.

Authors:  Yao Liu; Wei Liu; Qiu-Xian Peng; Jiang-Li Peng; Lin-Zhong Yu; Jian-Lan Hu
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-28       Impact factor: 2.629

6.  Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study.

Authors:  Wan-Tzu Lin; Yi-Jun Liao; Yen-Chun Peng; Chung-Hsin Chang; Ching-Heng Lin; Hong-Zen Yeh; Chi-Sen Chang
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

Review 7.  Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.

Authors:  Darren M Brenner; Brian E Lacy
Journal:  Am J Gastroenterol       Date:  2021-08-01       Impact factor: 12.045

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.